

SIDE EFFECTS OF CHEMOTHERAPY



What we will cover today

• What is chemotherapy

02 Background of chemotherapy in pancreatic cancer

1 Side effects; prevention, assessment, treatment and support





WHAT IS CHEMOTHERAPY?

3






- Chemotherapy is a modality of cancer therapy that involves the administration of chemical agents to destroy cancer cells.
- The aim of chemotherapy is to cure where possible and to palliate where cure is impossible
- Chemotherapy is 'cytotoxic' meaning cell killing

How chemotherapy works

- Our bodies are made of billions of individual cells.
- In the centre of each living cell is the nucleus. The nucleus is the control centre of the cell. It contains chromosomes, which are made up of genes
- As 1 cell divides into 2 each cell will contain the same set of genes, these 2 will split to make 4 and so on and so forth.

https://www.cancerresearchuk.org/aboutcancer/treatment/chemotherapy/howchemotherapy-works









- In cancer an abnormal cell keeps dividing till there is a mass of the abnormal cells and this mass become a tumour
- Chemotherapy damages the genes inside the nucleus of the cells
- Cancer cells divide much more often than normal cells and this is why chemo is much more likely to kill them.

https://www.cancerresearchuk.org/aboutcancer/treatment/chemotherapy/howchemotherapy-works





CHEMOTHERAPY & PANCREATIC CANCER



How we use chemotherapy in PDAC



- **Neo-ADJUVANT** (before surgery to try to shrink the cancer so that there's a better chance of removing it)
- **ADJUVANT** (after surgery to try to reduce the chances of the cancer coming back)
- **LOCALLY ADVANCED** (to control the growth of cancer, extend life and maintain quality of life)
- **PALLIATIVE** (to control the growth of the cancer, extend life and maintain quality of life)



Neoadjuvant Treatment – ESPAC 5



Artic

Oa

The results of this trial provided evidence for short-course chemotherapy before surgery in **borderline resectable** pancreatic ductal adenocarcinoma THE LANCET Gastroenterology & Hepatology

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Paula Ghaneh, Daniel Palmer, Silvia Cicconi, Richard Jackson, Christopher Michael Halloran, Charlotte Rawcliffe, Rajaram Sripadam, Somnath Mukherjee, Zahir Soonawalla, Jonathan Wadsley, Ahmed Al-Mukhtar, Euan Dickson, Janet Graham, Long Jiao, Harpreet S Wasan, Iain S Tait, Andreas Prachalias, Paul Ross, Juan W Valle, Derek A O'Reilly, Bilal Al-Sarireh, Sarah Gwynne, Irfan Ahmed, Kate Connolly, Kein-Long Yim, David Cunningham, Thomas Armstrong, Caroline Archer, Keith Roberts, Yuk Ting Ma, Christoph Springfeld, Christine Tjaden, Thilo Hackert, Markus W Büchler, John P Neoptolemos, for the European Study Group for Pancreatic Cancer

Chemo-radio before surgery Proportion of ppl having chemo +/- radiotherapy before whipple's surgery (2019-2021)

- England (2019-21) 9%
- Wales (2022) 7%

https://www.thelancet.com/action/showPdf?pii=S2468-1253%2822%2900348-X https://www.natcan.org.uk/audits/pancreatic/

Evolution of adjuvant chemotherapy



С	ESPAC-1 Chemotherapy (5-FU)	CONKO-001 Chemotherapy (Gemcitabine)	ESPAC-3 5-FU OR Gemcitabine	ESPAC-4 GemCap	PRODIGE-24 Gem vs mFOLFIRINOX
	2004	2007	2010	2017	2018

Chemo-radio after surgery					
Proportion of ppl having chemo +/- radiotherapy before surgery					
 England (2019-21) 56% 					
 Wales (2022) 44% 					

Neoptolemos et al NEJM 2004; Oettle et al JAMA 2007; Neoptolemos et al JAMA 2010; Neoptolemos et al Lancet 2017; Conroy, NEJM 2018 https://www.natcan.org.uk/audits/pancreatic/

Benefits of a palliative chemotherapy 1st line



	Control arm	Experimental arm	Improvement between arms	What did we learn?	
Gem	5FU: (4.4 months)	5.6 months	1.2 months	Gemcitabine standard first line	
Gem + Erlotinib			15 days	No clinically significant benefit	
Gem +Gem:7.1 monthsCap(6.2 months)		7.1 months	0.9 month	Moderate clinical benefit	
FOLFIRIN OX	Gem: (6.8 months)	11.1 months	4.3 months	Best survival results	
Gem + NabPac	Gem: (6.7 months)	8.5 months	1.8 months	No QoL data No comparison with FFX	

Burris, et al JOC 1997; Moore et al JCO 2007; Cunningham et al JCO 2009; Conroy et al NEJM 2011; VonHoff et al 2013 https://www.natcan.org.uk/audits/pancreatic/

Benefits of a palliative chemotherapy 1st line



	Control arm	Experimental arm	Improvement between arms	What did we learn?
Gem	5FU: (4.4 months)	5.6 months	1.2 months	Gemcitabine standard first line
Gem + Erlotinib	Gem: (5.91 months)	6.2 months	15 days	No clinically significant benefit
Gem + Cap	Gem: (6.2 months)	7.1 months	0.9 month	Moderate clinical benefit
FOLFIRIN OX			4.3 months	Best survival results
Gem + NabPac	Gem: (6.7 months)	8.5 months	1.8 months	No QoL data No comparison with FFX

Burris, et al JOC 1997; Moore et al JCO 2007; Cunningham et al JCO 2009; Conroy et al NEJM 2011; VonHoff et al 2013 https://www.natcan.org.uk/audits/pancreatic/

Benefits of a palliative chemotherapy 1st line



	Control arm	Experimental arm	Improvement between arms	What did we learn?	
Gem	5FU: (4.4 months)			Gemcitabine standard first line	
Gem + Erlotinib	Gem: (5.91 months)	6.2 months	15 days	No clinically significant benefit	
Gem + Can	Gem: (6.2 months)	7.1 months	0.9 month	Moderate clinical benefit	
FOLFIRIN OX	Gem: (6.8 months)	11.1 months	4.3 months	Best survival results	
Gem + NabPac	Gem: (6.7 months)	8.5 months	1.8 months	No QoL data No comparison with FFX	

In England (2020-2021):.

• 8734 people had stage 4 pancreatic cancer. 25% of these people received some form of treatment for pancreatic cancer


Burris, et al JOC 1997; Moore et al JCO 2007; Cunningham et al JCO 2009; Conroy et al NEJM 2011; VonHoff et al 2013

https://www.natcan.org.uk/audits/pancreatic/

Benefits of a palliative chemotherapy 2nd line



	Control arm	Experimental arm	Improvement between arms	What did we learn?
FOLFOX	BSC: (2.3 months)	4.8 months	2.5 months	FOLFOX standard second line
FOLFOX	5-FU: 3.3 months	5.9 months	2.6 months	FOLFOX standard second line
5-FU + liposomal irinotecal	5-FU: 4.2 months	6.2 months	1.3-2 month	5-FU + liposomal irinotecan standard second line



Pancreatic





SPECIAL ARTICLE

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up $\stackrel{\textrm{\tiny{fit}}}{\rightarrow}$

T. Conroy^{1,2}, P. Pfeiffer³, V. Vilgrain^{4,5}, A. Lamarca⁶, T. Seufferlein⁷, E. M. O'Reilly⁶, T. Hackert⁹, T. Golan¹⁰, G. Prager¹¹, K. Haustermans¹², A. Vogel¹³ & M. Ducreux¹⁴, on behalf of the ESMO Guidelines Committee⁺


¹Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandeourve-lex-Nanor, ²AFRMAC, équipe MICS, Université de Lorraine, Nanov, France: ¹Department of Netoclogy, Odense University Hospital, Odense, Demarki, ²Centre de Rechercher sur l'Inflamation U 1149, Université de Israï Cite, Paris, ²Department of Radiology, Beaujon Hospital, APHP Word, Citchy, France: ¹Department of Medical Oncology, The Christie NHS Foundation Tust, Manchester, UK, ²Department of Internal Medicine (Juli University) Hospital Hamburg-Eppendorf, Hamburg, Germany, ¹¹Department of Necolical Menorial Stana Kettering Cancer Center, New Vor, USA; ¹²Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany, ¹¹Department of Medicine (Division of Oncology, Netalical University of Viena, Viena, Vena, Sutaria, ¹¹Department of Adations 11 Avio Viniversity, Tel Aviv, Irasel, ¹¹Department of Medicine (Division of Oncology, Netalical University of Viena, Viena, Netalia, ¹¹Department of Adation Oncology, University Hospital Leuven, Leuven, Belgium, ¹¹Department of Gastroenterology, Hepatology and Endecrinology, Hanover Medical School, Hannover, Germany, ¹¹Università Paris-Scalo, Gustare Roussy, Insem Unité Dynamique des Cellules Tumorales, Villeur, France

Available online 9 September 2023

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Conroy et al 2023 Annals of Oncology

https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2823%2900824-4





Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Conroy et al 2023 Annals of Oncology

https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2823%2900824-4

T. Conroy^{1,2}, P. Pfeiffer³, V. Vilgrain^{4,5}, A. Lamarca⁶, T. Seufferlein⁷, E. M. O'Reilly⁸, T. Hackert⁹, T. Golan¹⁰, G. Prager¹¹, K. Haustermans¹², A. Vogel¹³ & M. Ducreux¹⁴, on behalf of the ESMO Guidelines Committee^{*}

¹Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, ²APEMAC, équipe MICS, Université de Lorraine, Nancy, France; ¹Department of Oncology, Odense University Hospital, Odense, Denmark; ⁴Centre de Recherche sur l'Inflammation U 1149, Université Paris Cité, Paris, ¹Department of Radiology, Beaujon Hospital, APH Mord, Clichy, France; ⁵Department of Medical Oncology, The Christie NIS5 Foundation Trust, Mancheser, UK: ⁵Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany, ¹⁰Department of Medical Oncology, Interistic State States, ¹¹Department of Medical Cancer, Tel Aviv, University, Tel Aviv, Israei; ¹¹Department of Medical Cancer, Memory, ¹⁰Satoriusticus, Beba Medical Cancer, Tel Aviv University, Tel Aviv, Israei; ¹¹Department of Medical on Cology, Medical University of Vienna, Vienna, Austria; ¹¹Department of Radiation Oncology, University Hospitala Leuven, Leuven, Belgium; ¹¹Department of Gastroenterology, Hepatology and Endocrinology, Hanover Medical School, Hannover, Germany, ¹¹Canversité Paris-Scale; Gustave Rousy, Inserem Unité Dynamique des Cellules Turorales, Villeiu/, France



Fitness and performance status



Performance status is assessed pre chemotherapy and prior to each chemotherapy cycle

Grade 0 - normal activity levels, can carry out strenuous work /activity with no restriction Grade 1 – some restrictions on strenuous activity but is able to carry out light work/ housework

Grade 2- unable to work but can manage own care and is ambulatory

Grade 3 – limited self care, sitting or in bed more than 50% waking hours

Grade 4 – bed or chair bound , needing assistance with self care

Treatment decision is influenced by baseline performance status PS 0-1 Fit enough for Triplet chemotherapy (FOLFIRINOX) Ps 1 -fit enough for Gemcitabine / Abraxane PS 1-2 fit enough for single agent Gemcitabine

https://ecog-acrin.org/resources/ecog-performance-status/ <u>Risk Factors for Chemotherapy-Related Toxicity and Adverse Events in Elderly Thai Cancer Patients: A Prospective Study. - Abstract</u> <u>- Europe PMC</u>





ASSESSMENT & TREAT

18

Preparing for treatment







Gentle exercise



Emotional well-being



Diet and digestion



Treat any symptoms

Information sharing



Chemotherapy for pancreatic cancer

This fact sheet is for anyone who wants to know about pancreatic cancer with chemotherapy. It explains how ch is given, the different drugs used, the main side effects chemotherapy and how these are managed.

Contents

Pancreatic

Cancer

Key facts
Chemotherapy for pancreatic cancer
What are the advantages and disadvantages?
How is chemotherapy given?
Check-ups before and during treatment
How does chemotherapy affect the blood?
Other side effects of chemotherapy
Diet and chemotherapy
Diabetes and chemotherapy
What happens after chemotherapy?
Coping with chemotherapy
Questions to ask your doctor or nurse
Further information and support

This information is for people with the most common type of pancre pancreatic ductal adenocarcinoma. People with pancreatic neuroend cancers may have different chemotherapy. Neuroendocrine Cancer L information at: neuroendocrinecancer.org.uk



FOLFIRINOX for pancreatic cancer

This fact sheet is for people with pancreatic cancer who having FOLFIRINOX chemotherapy.

FOLFIRINOX is one of the main chemotherapy treatments for pancrea It is made up of several different chemotherapy drugs.

Each hospital may do things slightly differently, and treatment will van on your cancer. Speak to your doctor or nurse about your treatment.

Contents

0

What is FOLFIRINOX?	
How is FOLFIRINOX used?	
How is FOLFIRINOX given?	
What are the side effects of FOLFIRINOX?	
Further information and support	

You can also speak to our specialist nurses on our confic Support Line. Call free on 0808 801 0707 or email nurse@pancreaticcancer.org.uk

Read more about the other chemotherapy drugs used fo pancreatic cancer on our website at: pancreaticcancer.org.uk/chemotherapydrugs

Read more about chemotherapy in our fact sheet: Chemotherapy for pancreatic cancer Or on our website at: pancreaticcancer.org.uk/chemothe

Order our publicatons online

Pancreatic Cancer U K

Nab-paclitaxel (Abraxane®) for pancreatic cancer

This fact sheet is for people with pancreatic cancer who want to know more about the chemotherapy drug nab-paclitaxel.

Nab-paciitaxel is used with another chemotherapy drug called gemcitabine (Gemzar^e). This may be an option for people with advanced pancreatic cancer.

Each hospital may do things slightly differently, and treatment will vary depending on your cancer. Speak to your doctor or nurse about your treatment.

Contents

low is nab-paclitaxel used?	2
fow is nab-paclitaxel given?	2
What are the side effects of nab-pacilitaxei?	
urther information and support	

You can also speak to our specialist nurses on our confidential Support Line. Call free on 0808 801 0707 or email nurse@pancreaticcancer.org.uk

Side effects

- Side effects are unavoidable but often manageable
- Different drugs cause different side effects
- Important to recognize that **1 in 10** patients may be admitted to hospital with side effects from chemotherapy
- I in 100 patients may die from life threatening toxicity from chemotherapy
- Common side effects are 10-100 (>10%)
- Occasional side effects are 1-10 (<10%)

https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.e14508

Consent forms for SACT (Systemic Anti-Cancer Therapy) | Cancer Research UK 2024



Common side effects

- Nausea and vomiting
- Diarrhoea
- Fatigue
- Mucositis
- Alopecia
- Neutropenia
- Anaemia
- Risk of bleeding
- Plantar Palmar Erythema
- Rash
- Cold sensitive paresthesia /neuropathy

How we assess & grade toxicities

The UK Oncology Nurses Society (UKONS) 24 Hour Triage Tool is a risk assessment tool that healthcare professionals use to prioritize the problems of patients calling 24-hour advice lines for oncology and haematology



https://www.ukons.org/site/assets/files/1134/triage_tool_poster.pdf

UKONS ONCOLOGY/HAEMATOLOGY ADVICE LINE					
All Green = self care advice 📝 1 Amber = review within 24 hours 🔯 2 or more amber = escalate to red 🔯 Red = attend for assessment as soon as possible 🐼					
Patients may present with problems other than these loted being, these small be rep-	Notes in general still publics where the theore theorem the functional two starts and the segment as "where 's the log place intellity. Functional and where the ND COLD annum tooling their yOD is assore the service of the publics and/or solid values of the segments.				
CAUTION! Place rate patients who are reacting or have reacted IMMUNOTHERAPY	may present with the	ainent related problems at anytime staring t	maineni or up in 12 months afternands. If you a	re seare aloosi the patient's regimer, be savi	instant follow intege symptom assessment.
👃 Toxicity/Symptom 👃	v 🛛	☑ 1	2	B 3	22 4
FOVER - resulting or has resulted lipitesis Anti Carson Trademost (MACT) within the last 0.8 south or immunocompromised.	-	2 TelePersonal State of a second state of the ALET spatiants who have taken analyze at this of reputs - If to dealed do a reserve.	an a	nat present with an alcournal tanget stars	int may still have an infection and in
Chect pain 2024 not and intracenses by lensis Anti Canzer Trackment writt environed by secology or carmatising trans.	liere.	Advisos TALENT ALS for modical assumants 198 1981 el Informational IdaC In glass annange for disconsection.			
Syngapse analytic attributer frames of them and/s solution a new sequence of them and/s for 1 is springer server 7 in production of them, where them is provided attributer of the solution of the second springer of springer of the solution of the solution of the solution of the solution of the solution of the solution of the solution invalues of the solution of the solution of the solution of the solution invalues of the solution of the solution of the solution of the solution.	New or so change from roomal	New search charteres, of levals with moderate exercise.	Non-most during all leads with with minimal exercise.	Unotions of levels at out.	Life from the ing symptom.
Verfaureance Stafas So there barrs a record change is performance status?	He change to pre-toutment resonal to or Fully antive, although to savy or all pre-to-save performance solution at mathematics.	Restricted in physically stremanos articity lost ambeddency and althe in sarry sait wards of a light seadent ary nature, such as light beautranets or affine such.	Ambulatory and capable of all self-sare fact makin in sary and any serie axistities. Up and almak more than 12% of oaking hears.	Capable of only finited off ann, conferred is load to chair for more from 80% of walking bours.	Completely disibled Convert comp and any oil com. Totally cost and to lead or obtain
Start Notation ten enserg sign han links secured for 1 ten enserg sign han links secured for 1 ten enserg times in a 28 hour period? Is there any datasetical pairs or discontinut? So they apartiest taken any activities densel and and any 1 in they apartiest taken any activities densel and and taken any activities and activity the period of the secure and the secure and the secure and the secure and the period of the secure and the secure and the secure and the secure and the security is densel and the secure and the secure and the secure and the secure and the secure and the secure and the	Hanne or no change from rearmal.	Internate of up in Theorem internation of day uses per instantonic memory or mild prevent in the other products. Date interest finish. Other memory angle. Other interest finish. Other periods and date research and date research.	Instrument of type to 6.4 replaced as a skep or mean details instrument in mattemp workput or mean-barrand meansmost or managements are sampling. Once primery of DMM Detains mind a serupt of dimensional and another taking regiment quark to an advance and their taking regiment quark to an advance and the sample	Increase of up to 2.4 epicodes a stay or process increase is a staying and put or increasing out of the energy and put of algorithms.	Internation III optimizing a slag or granity Informity distribution
Constignation too long close a serie sparses? view any adversaria sparses? to the any adversaria sparses and a series to the particulation of sparses and software.	Same or re- sharing a frame manual	Mildrin on honor I more maril for 28 hours over per leminent consul Distance support or medications.	Modewate : no locar featurement for 28 hours over per locarment normal. If searched with path / conting move to real. Review fluid antificiates; Review fluid antificiates; Review fluid antificiates;	Income - no income more reaction for The Statement reaction and the Statement reaction.	Fin lancer i more most for child bases - consister panelytic fina
In Starty Disarder Anders and Starty Disarder Anders any shares in the sine shart? Anders any shares in the sine's factor shart? Anders any shares in the sine's factor share the start shares of the sine share Anders any shares and the sine's factor shares and the sine shares Anders and shares and the sine shares and the sine shares be spine shares and the sine shares and the sine shares be spine shares and the sine shares and the sine shares be spine shares and the sine shares and the sine shares and the sine shares be spine shares and the sine share	Norm of the American Anno control	Mild symplems. Minimal Increase in Annyanny unyanny Agauria-maskaria. Right real-arises in molyauk. China ware taking in molyauk. China is arise taking in the analysis.	Madeutergesptens. Madeute increase in frequency organization of the second Madeuteration of the first second second Scient many fields. Solders a first second first analysis.	Anner ya pieros Produkto denos atino desentinos terro incontracion Rice no increasing harmoducio Energe endantino in adquit	Little or ne calme subject.
40184 FFF reactivity lynkemic.Anti Cansor Treatment (ALCT) and EFF at risk of Immuneappression.		linear t	- 36.9° (- 80
videotioni (as the patient island: their temperature? [Far when?] Mark 1.87 / Frynsaid are there to halfs, path, bening "Uning the of filling patient grands path, bening "Uning the of filling patient grands and phane path, and phane that adduct? and phane path, and a what adduct?	-	Londinal vigns of infaction otherwise generally unit	Tapes of information and general dynamical 4 if an anti-transmit failmen multi-specific topics pathway. 4 if not an active transmost a storage upgent topic topics.	Egen of an one symptometry induction.	Life the atoming again.
NALLOOA Ince many days? What is the patient's and inialas? Is the patient's skiling antienetiss as preached? seens patient's arisesy mulguit and colour.	tere.	Able to exhibit conservable totals. Reduce and investigations of the local parity.	Alde to estidately balance is significantly decreased. Review and events according to local policy	be aged	land bilake
As existing the data of the second se	-	13 replandes in 24 hours. Review and provides associating to local paring.	E-Complexities in 24 Process. Annual sector sector second reg to band particip	8 Marghadas in 28 ha an.	-18 rglander in 26 haars.
Staff / distances from samely dipole of theme any mouth ultren T where mendmen of infersion? Jor they able is not and abisis? bases partient's urbany subput and uttime.	line.	Painlessulaers analler erytheme, mild userenss kut able to sat and dirick sommally. Use encodiments or directed.	Paintial science, and/or any/herne, mild sciences had address east and administrationally. Constitute paints, remainistration as distributed, details sciencing of flactule. Use parts filters where as a tablet or mean-timesis.	Panelul anytheres, still using eating and decising	Significant pairs, mintered intelex andler reduced unitary subject.
teo recia Visi a appetite Tan' Han bia recently obargen? La present surgich han? La dia second second recentgradian : if provider its specific problem/specifics.	hane or na shange from exernal.	Loss of appetite without a location in entry habits Denney adves	Oral Inteller alternet attiteut significant untight lass ar malnairtiter. Inteller anteine	Coal Initiate altered in association with significant weight Instruction time.	Life the atomic group listing, such as collapse
Talin K. J. a new problem 1 Where is 37 New long have you had 33 Kare you fullow any path Alford Is there any soreling or reduced 1 Typica associated with working or colors associate theorem are reduced. Such pairs constraints of the reducting of advances associate theorem. (MECC)	Norse or no shange from nor sol.	Mild pairs out interfering with daily articles. Advise appropriate and pro-	Madeuie pain interfering with dely anti-time	Becare pain interfacing with daily activities.	levers slading pan
Accurate sectory of installar's sector definition of its in definition matility/function.1 (c) generated in training matility/function.1 (c) generated in training matility/function.1 (c) generated in the sector of the sector	Nere or no drange from normal.	Mild parenthesis, subjective seatherse. No loss of function. Contact the advice loss secondarily if anterimentation.	Mild or enables in sensory loss, made set a sensitive a, wild analyzers with restrict of function.	Reverse Lensary laws, parentifeetia or senal new that interference with functions.	Protys.
Confuction/cognitive distantance of the a new symptom? How long have you had this symptom? Is it getting serve? a it constant? Any resent change in medication?	Rene or no drange frammarmat	Malidiserientation net interfering with anticities of daily long. Eight decrease in level of alertows.	Moderate regulate dealedly onder dispriserus in limiting antidities of daily living	Secure regult in dealering and to secure methodary securely limiting activities of only house, Alternal hout at a secure income. MRT Cognit Assessment in Links.	Life thread using consequences, See of conversion encoder module. 989 : Urgent another module.
utigue a deta a seen produken?" is it getiting women? Here many daps? ary other associated symptoms? Do provider exhausers?	hinne ar na shange fram nannal.	Transand falgur last not affecting connections of article fant an expected with interveltant with article facencies	Madeute or interfering with same normal articular.	In a spin and a line of a later way and the spin start and a set of the spin start and th	Real-siden or disabiling
Left Name 14, 14 and Leadland or generalized? Here lang have you had 10 k it getting users? In high free particularly get a particular high of the second second second second second second second high second second second second second second second high second second second second second second B is an analysis for the second second second second B is an analysis for the second second second second B is an analysis for the second second second second B is a second second second second second second second B is a second second second second second second second B is a second second second second second second second second B is a second s	Rene or no shange fran narmal	Radi securing s10% ELL with or without symptom, such acynoritie, harring lighteen.	Radi severing 10: 2011 FLA shart to initiag meaning atticture of data to agree with white atticture of data to agree with explored atticture of the second second types. Constraints of the second second second second attack of the second second second second attack of the second second second second attack of the second second second second second attack of the second second second second second attack of the second sec	Sectore of the sector of the s	<u>en idal y print</u> a ¹ ni ing sel ^a nan
8 as new problem? In its continuous? What annuari? there hear? Law you taking antinagularits? It Harmetings, Influence insulg public lense.	Rene or no disarge from normal.	Mild, will limited controlled by communities measures. Consider amonging a full blood court.	Modernie Menting 999 : Urgeni anatoreni in ABE	Next Meeting WE Digest addresses in ARE	Manufer Marel 1991 - Degard anarameri in 1942.
Truising off a new problem? Is it included or generalized? Is there any incurse involved?	None or no change from normal.	Constituent - single to share to only once area.		Multiple sites of locating or one large site.	
Scalaringe gradulares office even problem? Any environment pair? Any sheet distortered? Any distort problem problem, eyes?	New or so thange from record.	Mial symptoms with interfering with functions		spegians interfering with function analyse ary	
Falinear Flavtar syndrome Fon active real UAT through follow drug specific pathoays long may need to be supervised and medical review arranged.	line.	Mild numbers, linging, and ling of hands and/or feet with or without pairs or redress. Test hands and here	Pain fail real real analyse scening of hands and/or face. Pollow does see if a polloway is not require does whether or to constrain defaults. Each match face.	Minist democranities, climation, Ministring Follow drug questils publicate - among early within 21 hours. May require down reduction or insulement d defense service lites.	and analos pain. nel appointement for review by questafiet bases effered.
International http://www.after.adure.a	line.	Rom Vestaans. Review The result day	Valuation dag nit brown Anange argent motes		22
So Do Constantia operational De autores programmento Sociedade appropriational operations appropriational operations appropriational operations appropriate operations appropriate oper	All fightis reserved Al tradie to representation des and represents faiteste reprised trainer	nor guarantaan as to the annurary completeness or a speciality for any landing loss of demage schedunger	n Hanguarry of any of Parconducts of Welstand Mirandonatas no. Annual by the search the test. These asing the first details to	TO RE-ORDER THE POSTER, DAMA STUDIO	etalfororfrag co.uk form bit tan

How we assess & grade toxicities



Grades Grade refers to the severity of the AE.

The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline

- **Grade 1 Mild;** asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
- **Grade 2 Moderate**; minimal, local or non-invasive intervention id; limiting age-appropriate instrumental ADL*.
- Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**.
- Grade 4 Life-threatening consequences; urgent intervention indicated.
- Grade 5 Death related to AE.



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

https://ctep.cancer.gov/protocoldevelopme nt/electronic_applications/docs/CTCAE_v5_ Quick_Reference_5x7.pdf



Please download and install the Slido app on all computers you use






In your practice what do you see as the impact of poorly controlled SE?

(i) Start presenting to display the poll results on this slide.

Chemotherapy induced nausea & vomiting





 Nausea and vomiting is a protective reflex to toxins

 Aims to get rid of toxins and/or prevents further ingestion

 Chemotherapy Trigger Zone in the brain stimulated by the chemotherapy drugs and produces a response effect

Source: Katzung BG, Masters SB, Trevor AJ: Basic & Clinical Pharmacology, 11th Edition: http://www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Risk Factors for Developing CINV



- <50 years of age
- Female
- History of motion sickness
- History of pregnancy related sickness
- Alcohol intake
- Vomiting pre chemotherapy disease related
- How emetogenic the chemotherapy regimen is

Types of CINV

- Anticipatory conditioned to sights/smells/ places
- Acute within first 24-48 hours
- Delayed-ongoing after 48 hours
- Breakthrough- occurs within 5 days of starting antiemetics
- Refractory- does not respond to treatment

Management of CINV -pharmacological approach



Medication Type	How does it work?	Generic Examples			
Serotonin (5-HT₃) receptor antagonist	Blocks the brain and gut receptors for	ondansetron (oral, IV disintegrating tablet)			
	serotonin. Inhibits serotonin, substance	granisetron (oral, IV, patch)			
	that primarily triggers N, V during first	palonosetron (oral, IV longer-acting lasting for 3-5 days)			
	day of therapy (Day 1)	Additional 5-HT₃ receptor antagonists: tropisetron			
Neurokinin 1 (NK1) receptor	Blocks NK1 receptor, and substance P, a	aprepitant (oral), fosaprepitant (IV), netupitant or			
antagonist	substance in brain's vomiting center	fosnetupitant (oral or IV used with palonosetron, respectively),			
		rolapitant (oral)			
Steroids (Corticosteroids)	Augments the effects of other	dexamethasone (DEX) (oral, IV)			
antiemetics		methylprednisolone (oral, IV)			
Centrally acting receptor antagonists Blocks a series of receptors that trigger		prochlorperazine (oral, IV, S), promethazine (oral IV, S),			
like Dopamine receptor antagonist	or relay the nausea signal in the brain	metoclopramide (oral, IV, disintegrating tablet),			
(DOP) and other mechanisms		olanzapine (OLZ), (oral, disintegrating tablet, IM)			
Anti-anxiety agents	Benzodiazepines can reduce anxiety	lorazepam (oral or IV)			
	that can help \downarrow anticipatory N, V	alprazolam (oral, liquid, disintegrating tablet)			
	vomiting				
* <u>oral</u> : by mouth; IV: by vein IM; by injec	*oral: by mouth; IV: by vein IM; by injection into the muscle; S: suppository; patch: skin patch 1.				

Non-pharmacological approach





Chemo related diarrhoea

Chemotherapy drugs can damage the rapidly dividing cells of the GI mucosa causing inflammation and a disruption in the fluid balance .

The absorption of fluids is decreased , followed by increased secretion of fluids and electrolytes in the stools.

Chemotherapy drugs that can cause diarrhoea include Capecitabine, 5-flourauoracil, Irinotecan, Oxaliplatin, gemcitabine.

Patient information and counselling is paramount Encouraged to report issues

<u>Presentation of Agreed Documentation to the Network</u> <u>Governance Committee</u>





Management of chemotherapy induced diarrhoea



- Loperamide an OTC medication used to slow down the bowel movements
- Codeine can be used for its constipating effects
- Atropine for early diarrhoea if on Irinotecan
- Infection must be ruled out prior to administration of these drugs
- May need hospital admission
- Pancreatic Enzyme Insufficiency?
- Any other cause?
- Dose reduction

Chemotherapy related fatigue



One of the most underestimated side effects by HCP's



Usually happens in the first few day's post chemotherapy




Cumulative side effect , builds up as the chemotherapy progresses



Effects most of the patients normal Activities of Daily Living

Performance Status is assessed at baseline and before every cycle of chemotherapy



Strategies to manage chemo related fatigue



Medical

- Medication review adjusting chemotherapy dose can improve fatigue
- Managing reversible causes of fatigue
- Using dexamethasone to boost energy levels and appetite
- Treat poorly controlled diabetes
- Treat PEI

Lifestyle adjustments

- Encourage patients to rest when needed
- Try and maintain a regular sleep pattern
- Encourage patients to engage in walking, swimming or light exercise
- Plan to do their activities at times of the day they have the most energy
- Diet

Chemotherapy induced peripheral neuropathy




Chemotherapy-induced neuropathy is a serious clinical problem caused by a substantial number of cytotoxic drugs


Two of the most prominent neurotoxic chemotherapy agents are **paclitaxel and oxaliplatin**

Higher risk if people are having more than one type of drug or treatment that can cause nerve damage Have had anti-cancer drugs in the past that can cause peripheral neuropathy Have diabetes

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update 2020 Loprinzi et al <u>https://ascopubs.org/doi/pdf/10.1200/JCO.20.01399</u> Updates in the treatment of chemotherapy-induced peripheral neuropathy. Mezzanotte et al 2022 Curr Treat Options Oncol. 2022 January ; 23(1): 29–42. doi:10.1007/s11864-021-00926-0.



https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/peripheral-neuropathy







- Tingling, pins and needles or numbness in the affected area
- Pain, which can be mild or more severe
- Muscle weakness that makes it hard to walk, climb stairs or do other tasks
- Feeling light-headed or dizzy when you sit up or stand up
- Difficulty doing up buttons on clothing or picking up small objects
- Problems with balance, walking and coordination.



Please download and install the Slido app on all computers you use






What is proven to help in the treatment of CIPN pain?

(i) Start presenting to display the poll results on this slide.

Treatment

- Duloxetine is the only drug with sufficient evidence to support its use.
 30mg OD for 7 days and titrate in 30mg increments max 120mg daily
- Chemotherapy dose adjustment
- Complementary therapy
- Physio and OT referral
- Capsaicin cream

Do you see any other approaches used in your practice?



Pancreatic

CANCER UK


Bone marrow depression

Chemotherapy-induced BMD is the most common dose-limiting and fatal complication of cancer treatment.

It is caused by destruction of proliferating cells that produce mature red and white blood cells and platelets in peripheral circulation.

As immature cells in the marrow are destroyed, preexisting mature cells are eliminated, and **the nadir** of the individual's blood cell count is attained (7-14days)

At that time, cells are maturing and are ready to release into peripheral blood so within a short period the blood count has returned to near normal state and the next dose of chemotherapy is administered



https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-1770905.pdf

https://media.istockphoto.com/id/2151690171/vector/yellow-bone-marrow-and-red-bone-marrow-blood-cells-develop.jpg?s=612x612&w=0&k=20&c=jHy9UVj5ZcttERoG6FfDUFFw6C_ZBuiXsTJ6Gkc79zI=

Symptoms of a low red blood cell count

•Fatigue

- •Paleness of skin, lips and nail beds
- Increased heart rate
- •Easy tiring with exertion
- •Dizziness
- •Shortness of breath

Symptoms of a low white blood cell count

•Fever and chills

•Rash

•Diarrhoea

•Signs of infection (anywhere in the body):

- Swelling
- Redness
- An area that is warm to touch

Symptoms of a low platelet count

•Easy bruising

- •Bleeding: nose bleeds, gums or mouth
- •Tiny red spots on the skin
- •Blood in the urine
- Dark or black bowel movements
- The symptoms of bone marrow
- suppression may resemble other medical conditions or problems. Always consult your physician or nurse practitioner for a diagnosis.





Febrile neutropenia (FN) is a life-threatening complication of cancer chemotherapy and is considered a medical emergency.

National guidance has been issued by NICE and includes the following key recommendations

- Hospitals should have a neutropenic sepsis policy, which includes management pathway
- Patient information and emergency contact instructions
- Risk assessment and identification of high and low risk patients
- Training and education for HCP in the recognition and management of patients with suspected neutropenic sepsis

Overview | Neutropenic sepsis: prevention and management in people with cancer | Guidance | NICE

Oral side effects




Oral toxicities are common

Chemo effects rapidly dividing cells such as the oral mucosa

Mucositis is characterised by erythema and ulceration of the mucosal lining of the GI tract.

Fungal infections (Oral thrush) is a common side effect of cancer treatments.

Chemo weakens the immune system this makes it more difficult for the body to fight off the Candida infection.



https://www.soligenix.com/our-focus/oral-mucositis/

Management

Patient and loved ones education

Using soft toothbrushes and alcohol-free mouthwashes

Gelclair is an effective barrier as well as treatment helping to alleviate pain

Increased analgesia – in severe cases opioids may be used

Lignocaine lollies

Sucralfate to coat the mouth

Eating bland soft foods

Maintaining adequate hydration

Treatment breaks

Other influencing factors – diabetes, antibiotics







41

Emotional impact of chemotherapy



- Changing view of self
- Uncertainty
- Body image
- Relationship worries
- Financial worries
- Sex issues
- Social relationship changes
- Fear of side effects
- Symptoms of pancreatic cancer
- Preconceived idea about chemotherapy
- Fear of progression or recurrence
- Fear of dose reduction or stopping treatment
- Carer burden
- Depression and/or anxiety
- Spiritual crisis



Please download and install the Slido app on all computers you use





Who might be important to support your patients on chemo?

(i) Start presenting to display the poll results on this slide.



CASE STUDIES



Joan

58-year-old with BR Head of PDAC PS 0 Referred for neoadjuvant chemotherapy **Treatment plan – FOLFIRINOX**

Assessment for C2 TRT

PS 0/1 but clearly withdrawn N&V – worse D3-7 Diarrhoea on and off Weight loss of 2%

What's in our mind when we hear this? Pop in chat your thoughts





Assessment for C3 TRT

PSI N&V better Diarrhoea remains an issue but changed in nature – now experienced Day2-6 3 x a day 7-10 2x a day used loperamide PRN but not lots PEI symptoms better Weight further 3% WL Fatigue - persistent, impacting on ADL's and effecting quality of life

She is struggling to cope with uncertainty

What's on our minds here?

Pop your thoughts in the chat



Please download and install the Slido app on all computers you use





What might we do here?

(i) Start presenting to display the poll results on this slide.



Joan

Post cycle 3

PS1 SE better with dose reduction Energy levels up and down but feels 'OK' Seeing team at Maggie's

Ct scan after 6 cycles showed response to treatment, cancer shrinking away from vein

Surgery performed 6 weeks after 6th cycle of chemotherapy.

Joan then came back for consideration of adjuvant chemotherapy to prevent recurrence



68yo Met (liver) PDAC of the body of pancreas Referred for 2nd line palliative chemo 1st line treat Gem/Abrax (dose reduced due to <platelets from C5 & PN) Successful 1st line treatment – stable disease PS 1 Aware of prognosis – GP aware, referred to pall/supp care. On PERT SE – chemo induced peripheral neuropathy **'Feels pretty good'**

Active surveillance 6 weeks bloods CA199 with CNS & 12-week scans seen in clinic Controlled disease for 4-5 months approx. Called me with worsening symptoms – scan/bloods expediated DP Considered for 2nd line FOLFIRNOX

What might be in our minds when thinking about 2nd line treatment?



2nd line FFX started at a reduced dose

Pre C2 assessment HB 96 Neut 0.9 WWC 3.5 Platelets 90

Apyrexial, no obvs signs of infection PS stable

What's on our minds here?



Cycle 2 deferred a week given via protocol clinic

Pre C3 assessment Blood count within parameters Sore mouth Feels dry Feeling tired Is eating well but has lost 3lbs since assessment before C2.

What might be going on here?



Mid treat scan showed stable disease Weight stable PS stable

Attends for pre cycle 7 assessment

Does not want to continue with treatment, want to focus on QoL Time burden of treatment

Our support for those affected

• Specialist Nurse Support Line

0808 801 0707

Monday, Tuesday, Thursday Friday 9am-4pm 10am-4pm on Wednesdays

Email <u>nurse@pancreaticcancer.org.uk</u>

- WhatsApp 07816 408416
- Expert information: free, expert information about pancreatic cancer
- Webinars: learn more about managing pancreatic cancer



Circles, our new community



Share the highs, lows and everything in between with people who understand, who just "get it".

We have been speaking to the community about the needs of people affected by pancreatic cancer and how we can meet those needs to support even more people.

As a result, we've created Circles, a service that will allow people affected by pancreatic cancer to connect via groups (such as WhatsApp and Facebook groups).

If this is something you are interested in, then you can sign up by: scanning the QR code here or visiting https://www.pancreaticcancer.org.uk/circles-sign-up-form/

Watch this space for other services we'll be trialling too



Take home thoughts



- Communicated clearly and sensitively
- Consider wide support people need (for all those affected by PC)
- Deal with any added stressors works, finance, carer burden
- Symptoms of PC need to be proactively managed alongside
 SE of treatment
- Peer to peer support is proven a vital need
- Consider the holistic elements